Hyppää sisältöön, Avaa menu tai Hyppää yhteystietoihin.

Pörssikalenteri

Sisäpiirin kaupat

Seurantayhtiöt

Asetukset

Qlife Holding

0,041 SEK −2,86 %

HC Andersen Capital saa maksun yhtiöltä Qlife Holding DigitalIR/Corporate Visibility -sopimuksesta. Katso vastuuvapauslauseke.

4 sijoittajaa seuraa yhtiötä

qlifeholding.com/sv/investerare

Qlife Holding is a medical technology company. The company specializes in the research and development of IVD units. The units are used as biomarker tests in blood and are used as a complement to other tests in healthcare. Cooperation is also carried out with other actors on the market. Qlife Holding mainly operates on the Nordic market and is headquartered in Helsingborg.

Liikevaihto

17,99 milj.

EBIT %

−481,82 %

P/E -luku

-

Osinkotuotto %

-

Tavoitehinta

-

Suositus

-

Päivitetty

-

First North Stockholm

QLIFE

Päivän matalin / päivän korkein hinta

0,04 / 0,043 SEK

Markkina-arvo

26,27 milj. SEK

Vaihto

343,26 t. SEK

Vaihtomäärä, kappaletta

8,4 milj.

Viimeisimmät analyysit

Qlife - One pager - At-home biomarker and virus testing devices (Egoo System) company.

Qlife: Initiation of coverage by Redeye AB

Viimeisimmät videot

Qlife - LOI with major industry player in China for Egoo Health

Life Science seminar

Qlife - Presentation of Q2 2023

Pörssikalenteri

Osavuosikatsaus

11.11.2023

Suurimmat omistajat
Lähde: Millistream Market Data AB

Omistaja	Osuus	Ääniä
Försäkringsbolaget Avanza Pension	9,9 %	9,9 %
Nordnet Pensionsförsäkring	9,7 %	9,7 %

Inderes Premium

Premium ei aktivoitu

Tämä sisältö on vain Inderes Premium -käyttäjille.

Kirjaudu sisään Lue lisää

Näytä Kaikki sisältötyypit

Qlife: Wrap up from interview with CEO Thomas Warthoe

Qlife: Wrap up from interview with CEO Thomas Warthoe

Analyytikon kommentti19.09.2023 - Claus Thestrup

Qlife - LOI with major industry player in China for Egoo Health

Meet and ask questions to CEO Thomas Warthoe from Qlife on 19 September 2023 at 9.00 AM.

Webcast19.09.2023 - Claus Thestrup

Qlife: LOI (Letter of intent) with major industry player in China for Egoo Health.

Qlife: LOI (Letter of intent) with major industry player in China for Egoo Health.

Analyytikon kommentti15.09.2023 - Claus Thestrup

Life Science Seminar – Wrap up from our event last week – Thursday the 31st. of August.

Life Science Seminar – Wrap up from our event last week – Thursday the 31st. of August.

Analyytikon kommentti05.09.2023 - Henrik Ekman, Claus Thestrup

Bavarian Nordic BioPorto Gubra ExpreS2ion Biotech Holding

Life Science seminar

Webcast31.08.2023 - Emilie Håkonsson Lohse

Bavarian Nordic Gubra ExpreS2ion Biotech Holding Ascelia Pharma

Qlife – Takeaways from Q2 interview with CFO Kasper Rousøe.

Qlife – Takeaways from Q2 interview with CFO Kasper Rousøe.

Analyytikon kommentti25.08.2023 - Claus Thestrup

Qlife - Presentation of Q2 2023

Meet and ask questions to Qlife Holdings CFO Kasper Roussøe Thursday 24 August at 09.30. The event will focus on the recently released Q2 report and especially the turnout of the restructuring program and transformation into a new business model.

Webcast24.08.2023

Egoo Health prepares to enter the US market

Egoo Health prepares to enter the US market

Analyytikon kommentti23.08.2023 - Henrik Ekman, Claus Thestrup

Redeye: Qlife Q2 2023 - Cost reductions completed

Lehdistötiedote18.08.2023

Qlife - One pager - At-home biomarker and virus testing devices (Egoo System) company.

Qlife - One pager - At-home biomarker and virus testing devices (Egoo System) company.

Inderes analyysi08.08.2023 - Claus Thestrup, Philip Coombes, Henrik Ekman

Qlife: Wrap up latest news

Qlife - wrap up latest news

Analyytikon kommentti07.08.2023 - Claus Thestrup

Qlife Holding AB: Launch of Egoo Innovate at AACC - to promote faster and targeted implementation of critical biomarker assays into at-home testing

Lehdistötiedote27.06.2023

Qlife Holding AB: Qlife to make its Egoo technology available as an open system to facilitate development and accelerate revenue streams

Lehdistötiedote26.06.2023

Interview with CEO Thomas Warthoe and demonstration of the Egoo Health platform

Interview with CEO Thomas Warthoe and demonstration of the Egoo Health platform

Analyytikon kommentti20.06.2023 - Claus Thestrup

Qlife Holding – Introduction to market segment and demonstration of Egoo

Meet Qlife Holding’s CEO Thomas Warthoe who will tell us more about one of their segments; dieticians & nutritionist, who are dealing with patients with systemic low-grade inflammation, what it is, and what solution the company offer to this. This event will explain one of the main drivers for Qlife and Egoo Health.

Webcast15.06.2023

Redeye: Qlife Q1 2023 - Reducing costs

Lehdistötiedote29.05.2023

Qlife Holding – What happened during Q1-2023?

Meet Qlife Holding’s CFO Kasper Rousøe who will present their Q1 report. The company publishes the report on the same day as the event takes place. The event takes place on the 26th. of May from 12:00 – 12:30 CEST. After the presentation, you are more than welcome to ask questions.

Webcast26.05.2023 - Claus Thestrup

Presentation of Q4 & FY22 and update on ongoing rights issue by CFO Kasper Rousøe

Interview with CFO Kasper Rousøe about 2022 and what investors should expect in 2023.

Analyytikon kommentti20.04.2023 - Claus Thestrup

Qlife - Presentation of Q4 report and update on ongoing rights issue

Meet Qlife Holding's CFO Kasper Rousøe when he presents the Q4 report and gives an update on the ongoing rights issue. The event takes place on the 20th of April – at 13:00 CET. We expect the event to last for 30 min. including questions.

Webcast20.04.2023 - Claus Thestrup

Qlife: Fully secures ongoing rights issue with top guarantee commitments

Qlife fully secures ongoing rights issue with top guarantee commitments.

Analyytikon kommentti16.04.2023 - Claus Thestrup, Henrik Ekman